# A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

> **NCT01357850** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 82 (actual)

## Conditions studied

- Heart Failure, Congestive

## Interventions

- **DRUG:** GSK716155
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01357850
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-15
- **Primary completion:** 2012-09-18
- **Final completion:** 2012-09-18
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2017-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01357850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01357850, "A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01357850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*